BiotechTube
Vascular Flow Technologies

Vascular Flow Technologies

Dundee, United Kingdom· Est.
vascular-flow.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7M

Overview

Vascular Flow Technologies is a specialized medical device contract development and manufacturing organization (CDMO) with a proprietary technology platform. Founded in 2007 and based in Dundee, Scotland, the company leverages its Spiral Laminar Flow (SLF™) technology to assist partners in developing and commercializing improved cardiovascular devices. It operates a three-pronged business model: licensing its SLF™ technology, providing end-to-end device development services, and offering contract manufacturing in a Class 7 cleanroom. A recent milestone includes FDA clearance for an SLF™-enabled AV graft for hemodialysis, indicating progression into commercial-stage activities.

Cardiovascular

Technology Platform

Spiral Laminar Flow (SLF™) technology designed to restore natural helical blood flow patterns in vascular implants to reduce complications and improve patency.

Funding History

2
Total raised:$7M
Series A$5M
Seed$2M

Opportunities

The recent FDA clearance for its SLF™ AV graft opens a direct commercial pathway in the large hemodialysis market.
The company's integrated service model (development, technology licensing, and manufacturing) allows it to capture value across the medical device lifecycle and diversify its revenue streams.

Risk Factors

Commercial success depends on proving the clinical superiority of SLF™ technology in real-world use to drive adoption in a competitive market.
As a small private company, scaling manufacturing, sales, and distribution for its new product while maintaining service operations presents significant execution risk.

Competitive Landscape

The company competes in the vascular graft market against large, established players like Becton Dickinson (BD), Getinge, and W. L. Gore & Associates. Its differentiation is the proprietary SLF™ technology, but it faces challenges in market penetration, scaling, and competing with the extensive sales and clinical support networks of its larger rivals.

More companies in United Kingdom →